Interleukin-6 and the Risk of Future Cardiovascular Events in Patients With Angina Pectoris and/or Healed Myocardial Infarction

American Journal of Cardiology

Volumn 98, Issue 1, 2006, Pages 14-18

  Fisman, Enrique Z ^b,c,e   Benderly, Michal ^a,b   Esper, Ricardo J ^d,e   Behar, Solomon ^a,b   Boyko, Valentina ^a   Adler, Yehuda ^a,b   Tanne, David ^a,b   Matas, Zipora ^c   Tenenbaum, Alexander ^a,b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e UNIVERSIDAD DEL SALVADOR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; INTERLEUKIN 6; NITRATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SUDDEN DEATH; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; DEATH, SUDDEN, CARDIAC; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 33745145788     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.01.045     Document Type: Article

References (20)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Hoffmeister A., Rothenbacher D., Kunze M., Brenner H., and Koenig W. Prognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery disease. Eur J Intern Med 16 (2005) 47-52
3. Fisman E.Z., Motro M., and Tenenbaum A. Cardiovascular diabetology in the core of a novel interleukins classification. the bad, the good and the aloof. Cardiovasc Diabetol 2 (2003) 11
4. Lindahl B., Toss H., Siegbahn A., Venge P., and Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 343 (2000) 1139-1147
5. Rajavashisth T.B., Xu X.P., Jovinge S., Meisel S., Xu X.O., Chai N.N., Fishbein M.C., Kaul S., Cercek B., Sharifi B., and Shah P.K. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. evidence for activation by proinflammatory mediators. Circulation 99 (1999) 3103-3109
6. Rus H.G., Vlaicu R., and Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127 (1996) 263-271
7. Kosmala W., Przewlocka-Kosmala M., and Mazurek W. Proinflammatory cytokines and myocardial viability in patients after acute myocardial infarction. Int J Cardiol 101 (2005) 449-456
8. Biasucci L.M., Vitelli A., and Liuzzo G. Elevated levels of IL-6 in unstable angina. Circulation 94 (1996) 874-877
9. Mazzone A., De Servi S., Vezzoli M., Fossati G., Mazzucchelli I., Gritti D., Ottini E., Mussini A., and Specchia G. Plasma levels of interleukin 2, 6, and 10 phenotypic characterization of circulating T lymphocytes in ischemic heart disease. Atherosclerosis 45 (1999) 369-374
10. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
11. The Bezafibrate Infarction Prevention (BIP) Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
12. Papanicolaou D.A., Wilder R.L., Manolagas S.C., and Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128 (1998) 127-137
13. McCarthy M.F. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity. down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 52 (1999) 465-477
14. Volpato S., Guralnik J.M., Ferrucci L., Balfour J., Chaves P., Fried L.P., and Harris T.B. Cardiovascular disease, interleukin-6, and risk of mortality in older women. the women's health and aging study. Circulation 103 (2001) 947-953
15. Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger Jr. W.H., Heimovitz H., Cohen H.J., and Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999) 506-512
16. Fernandez-Real J.M., Vayreda M., Richart C., Gutierrez C., Broch M., Vendrell J., and Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86 (2001) 1154-1159
17. Gonzalez W., Fontaine V., Pueyo M.E., Laquay N., Messika-Zeitoun D., Philippe M., Arnal J.F., Jacob M.P., and Michel J.B. Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension. modulation of proinflammatory signals. Hypertension 36 (2000) 103-109
18. Tappia P.S., Troughton K.L., Langley-Evans S.C., and Grimble R.F. Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci 88 (1995) 485-489
19. Tracy R.P., Macy E.M., and Bovill E.G. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17 (1997) 2167-2176
20. Futterman L.G., and Lemberg L. High-sensitivity C-reactive protein is the most effective prognostic measurement of acute coronary events. Am J Crit Care 11 (2002) 482-486